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ABSTRACT 
Background: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious 
than interferon beta-1a in treating relapsing-remitting multiple sclerosis, but its efficacy 
relative to other more potent immunotherapies is unknown. 
 
Methods: We compared effectiveness of alemtuzumab vs. natalizumab, fingolimod 
and interferon β up to five years in propensity-matched patients with relapsing-
remitting multiple sclerosis from MSBase and four other observational cohorts. 
Annualised relapse rates, disability progressionaccumulation and disability 
regressionimprovement events were compared with clustered weighted models. 
Secondary analyses examined patients with high pre-treatment relapse rate or on-
treatment relapses. 
 
ResultsFindings: The cohorts consisted of 189 (alemtuzumab), 2155 (interferon), 828 
(fingolimod) and 1160 (natalizumab) patients. Compared to interferon, alemtuzumab 
was associated with lower annualised relapse rate (0·19 vs. 0·53, P<0·001), and 
similar disability outcomes in the overall cohort, and lower risk of disability 
progressionaccumulation (hazard ratio=0·64, P=0·018) and a higher rate of disability 
regressionimprovement in patients with prior highly active disease (hazard ratio=4, 
P=0·03). Compared to fingolimod, relapse rate was lower on alemtuzumab (0·15 vs. 
0·34, P<0·001). Importantly, no differences in relapse rate (0·20 vs. 0·19, respectively, 
P=0·78) and disability progressionaccumulation rates were found between 
alemtuzumab and natalizumab. Disability regressionimprovement rates were lower on 
alemtuzumab (hazard ratio=0·36, P<0·001) than natalizumab, particularly during the 
first year after commencing therapy. The results were largely confirmed by four 
sensitivity analyses. 
 
ConclusionsInerpretation: Alemtuzumab and natalizumab showed similar effects on 
relapse activity and disability progressionaccumulation rates in relapsing-remitting 
multiple sclerosis but natalizumab was associated with a greater chance of early 
disability regressionimprovement. Alemtuzumab was superior to fingolimod in 
mitigating relapse activity. 
 
Funding: This study was financially supported by National Health and Medical 
Research Council and University of Melbourne.  
  
TEXT 
INTRODUCTION 
Alemtuzumab, an anti-CD52 humanised monoclonal antibody, is a highly effective 
immunotherapy for relapsing-remitting multiple sclerosis (MS).1-3 Through a profound 
pan-lymphocyte depletion and sustained modification of lymphocyte repertoire,4 it 
achieves long-term disease stabilisation in most patients with previously active 
disease.5,6 Pivotal trials have demonstrated its superior effect on relapse activity and 
disability accrual compared with interferon β.2,3  
Recent onset of highly active MS, escalation of therapy to natalizumab or alemtuzumab 
following failure of oral medications7 or switch from natalizumab to alemtuzumab or 
fingolimod due to a high risk of progressive multifocal leukoencephalopathy8,9 are 
common scenarios in which alemtuzumab is used in clinical practice. However, there 
is presently no information about the effectiveness of alemtuzumab in comparison to 
the other more potent disease modifying therapies. Mixed-treatment analyses of 
alemtuzumab versus other licensed agents were performed during submissions to 
reimbursement agencies (e.g. the National Institute for Health and Care Excellence, 
UK) but public versions of these documents are heavily redacted. This much needed 
evidence is unlikely to emerge from randomised trials as the cost of such long-term 
multi-arm trials is prohibitive.  
Well characterised observational cohorts collect substantial amounts of longitudinal 
information representative of clinical practice. Several cohorts have recently generated 
valuable evidence regarding comparative treatment effectiveness, which is highly 
concordant with clinical trials.10 We have shown that in active MS, highly potent 
therapies, such as natalizumab or fingolimod, are more effective than injectable 
immunotherapies.11,12   
The present study compares relapse activity, disability progressionaccumulation and 
disability regressionimprovement between patients treated with alemtuzumab vs. other 
potent immunotherapies. First, we aimed to replicate the results of the pivotal trials of 
alemtuzumab vs. interferon β. Then, we explored the effectiveness of alemtuzumab in 
comparison with natalizumab or fingolimod over up to five years of treatment. 
 
 
METHODS 
The MSBase cohort study (registered with WHO ICTRP, ID ACTRN12605000455662) 
was approved by the Melbourne Health Human Research Ethics Committee, and by 
the site institutional review boards (or exemptions were granted, according to local 
regulations). Written informed consent was obtained from enrolled patients, as 
required. 
 
Patients and follow-up 
Longitudinal clinical data from 96 MSBase centres in 30 countries and patients treated 
with alemtuzumab from six MS centres in Cambridge,5 Cardiff, Bristol, Swansea,6 
Dublin and Dresden13 were extracted between November 2015 and June 2016 and 
evaluated for inclusion criteria. These consisted of the following: definite relapsing-
remitting MS,14,15 exposure to one of the study therapies, no prior exposure to 
hematopoietic stem cell transplantation, no participation in randomised clinical trials, 
minimum required recorded follow-up (12 months prior to treatment start and two on-
treatment disability scores ≥6 months apart) and minimum dataset (consisting of sex, 
age, time of first MS symptom, dates of clinical relapses, clinical MS course, disability 
score at treatment commencement (-6 months to +3 months), ≥6-month persistence 
on study therapy, ≥1 relapse experienced within the year before treatment, age ≤65 
years, time from first MS symptom ≤10 years and Expanded Disability Status Scale 
(EDSS) score ≤6·5.  
Treatment protocols, which involved alemtuzumab (12-24mg i.v. daily for five days 
(cycle 1) or three days (cycle 2)), interferon β-1a (44μg s.c. thrice weekly), fingolimod 
(0·5mg oral daily) and natalizumab (300μg i.v. every four weeks) were described 
elsewhere.5,6,11 Baseline was defined as the first commencement of the study therapy 
and patients were censored at discontinuing therapy, commencing the first post-
baseline disease modifying therapy or at the last recorded EDSS, whichever occurred 
first. 
The analysed data were recorded as part of quality clinical practice, mostly at tertiary 
MS centres, with data entry at the time of clinical visits. The MSBase protocol stipulates 
minimum annual updates of the minimum dataset, but patients with less frequent visits 
were not excluded. Data entry portals included iMed, MSBase online data entry 
system, PatientCare, MSDS or local data entry systems. Rigorous quality assurance 
procedure was applied (Table S2).16 
 
Study endpoints 
The primary endpoint was the on-treatment annualised relapse rate. Secondary 
endpoints consisted of the cumulative hazard of relapses, disability 
progressionaccumulation events and disability regressionimprovement events. 
A relapse was defined as occurrence of new symptoms or exacerbation of existing 
symptoms persisting for ≥24 hours, in the absence of concurrent illness/fever, and 
occurring ≥30 days after a previous relapse. Confirmation of relapses by EDSS was 
not required. Individual annualised relapse rate between baseline and censoring was 
calculated. 
Disability was scored by accredited EDSS scorers (Neurostatus certification was 
required at the participating centres), excluding any score recorded within 30 days of 
a previous relapse. The definitions of disability progressionaccumulation and 
regressionimprovement required confirmation over ≥6 months, as described 
elsewhere.17  
 
Matching and statistical analysis 
Matching and statistical analysis were conducted using R (version 3·0·3)18, in three 
separate paired matched analyses of alemtuzumab vs. interferon β, fingolimod or 
natalizumab. Individual Ppatients were matched on their propensity of receiving either 
of the compared therapies.12,19 Individual propensity scores were calculated using a 
multivariable logistic regressionimprovement model of treatment allocation that utilised 
demographic and clinical variables available at the time of treatment assignation as 
independent variables: sex, age, time from first MS symptom, EDSS, number of 
relapses in the prior 12 months, number of prior MS therapies, and the perceived most 
effective prior MS therapy. 
Patients were matched in a variable 2:1 ratio using nearest neighbour matching within 
a narrow caliper (0·1 standard deviations of the propensity score), without 
replacement. All subsequent analyses were designed as paired models with weighting 
to adjust for the variable matching ratio. A maximum cumulative weight for each 
matched patient was 1. The common on-treatment follow-up was determined in each 
matched pair as the shorter of the two patient follow-up periods (pairwise censoring), 
in order to control attrition bias.10  
Tests of statistical inference were carried out at α=0·05 with familywise Benjamini-
Hochberg correction for false discovery rate. After assessing normality of data 
distribution, annualised relapse rates were compared with a weighted negative 
binomial model with cluster effect for matched patient pairs and adjusted for visit 
frequency. Relapse rates at years 1-5 were compared with weighted paired t-tests. 
Cumulative hazards of relapses, EDSS progressionaccumulation and 
regressionimprovement events were analysed with weighted conditional proportional 
hazards models with robust estimation of variance (Andersen-Gill) adjusted for visit 
frequency. The proportions of patients free from relapse, EDSS 
progressionaccumulation and with EDSS regressionimprovement were evaluated with 
weighted conditional proportional hazards models (Cox) adjusted for visit frequency. 
Where the Pproportionality of hazards assumption was violated (assessed with 
Schoenfeld’s global test), interaction term for treatment and time was included in the 
multivariable models.  
Robustness of the statistically significant differences to unidentified confounders was 
quantified with Hodges-Lehmann Γ.20 Where no statistically significant differences 
were observed, analytical power was quantified as the minimum effect magnitude 
detectable within the available cohort at 1-β=0·8 using simulations (n=200). 
 
Secondary and sensitivity analyses 
Two secondary analyses and four sensitivity analyses were completed. The secondary 
analyses compared the therapies (i) among patients with high pre-baseline relapse 
activity (defined as ≥2 relapses within 12 months or ≥3 relapses within 24 months pre-
baseline, irrespective of treatment status) and (ii) any prior on-treatment break-through 
relapses. The former used a 10:1 variable matching ratio in order to maximise 
analytical power. The sensitivity analyses evaluated the robustness of the results to 
potential confounders, including matching (using 10:1 variable matching within a 
caliper of 0·4), pre-baseline follow-up (matching on the number of relapses in the prior 
24 months), MS phenotype (allowing inclusion of patients with secondary progressive 
MS), follow-up duration (including patients with ≥2-year on-treatment follow-up) and 
confirmation of EDSS progressionaccumulation/regressionimprovement events over 
≥12 months. 
 
Role of the funding source 
The study (including study design, the collection, analysis, and interpretation of data, 
writing of the report, and in the decision to submit the paper for publication) was 
conducted separately and apart from the guidance of the sponsors. 
 
 
RESULTS 
A total of 189, 2155, 828 and 1160 patients fulfilling the inclusion criteria and treated 
with alemtuzumab (from 1999), interferon β (from 1994), fingolimod (from 2010) and 
natalizumab (from 2006) were identified, respectively (Figure 1, Table S3). One 
hundred and five (55%) patients treated with alemtuzumab received two treatment 
cycles and 84 patients (45%) required additional treatment cycles. As expected, the 
four unmatched groups differed in their baseline characteristics (Table S4). As shown 
by the logistic regression models used to calculate propensity scores, patients 
commenced alemtuzumab earlier after their first MS presentation, at a younger age, 
and tended to have higher EDSS scores and pre-baseline relapse activity compared 
to the three other therapies (Table S5).  
The numbers of patients retained in the matched cohorts for all three pairwise primary 
analyses are shown in Table 1. The matching procedure significantly decreased the 
between-group differences in propensity scores from 0·24-0·44 to 0·0001-0·0026, 
corresponding to a >99·4% improvement in the balance between the compared 
groups. This is reflected by their close match on individual characteristics with 
standardised differences of ≤15% (Table 1). The median differences between baseline 
date and the date of the baseline EDSS were comparable between the matched 
cohorts (-14-0 days [quartiles -71 to +12], standardised difference 0.02-0.19). As a 
result of pairwise censoring, on-treatment follow-up was identical in the matched 
groups. The groups were not matched on the follow-up visit density, therefore all 
subsequent analyses were adjusted for visit frequency. 
Patients treated with alemtuzumab experienced a lower annualised relapse rate 
compared with interferon β (mean [95% confidence intervals] 0·19 [0·14-0·23] vs. 0·53 
[0·46-0·61], respectively, P<0·001; Figure 2). While a consistent decline in the relapse 
rate was observed in the interferon β group over the five years on treatment 
(representing time-dependent decline in relapse activity21), the difference between the 
groups remained significant throughout the follow-up. Cumulative hazard of relapse 
events was lower in the alemtuzumab group (hazard ratio 0·60, P=0·005). The primary 
analysis did not show any differences in the cumulative hazards of disability 
progressionaccumulation or regressionimprovement (P≥0·66). However, the 
secondary analyses (in addition to confirming the differences in relapse outcomes) 
showed that alemtuzumab was associated with a lower hazard of disability 
progressionaccumulation than interferon β in patients with high pre-baseline relapse 
activity and higher probability of disability regressionimprovement in patients with 
previous on-treatment break-through relapses (Table S6). 
Similarly, patients treated with alemtuzumab showed lower annualised relapse rate 
compared with fingolimod (mean [95% confidence intervals] 0·15 [0·10-0·20] vs. 0·34 
[0·26-0·41], P<0·001; Figure 3). This observation was consistent during years 1-3, for 
which sufficient cohorts were available. The difference in cumulative hazard of 
relapses failed to reach the level of statistical significance (P=0·18). More patients in 
the alemtuzumab group tended to remain free from relapses (hazard ratio 0·59, 
P=0·065). No between-group differences in the cumulative hazards of disability 
progressionaccumulation or regressionimprovement were observed. 
The comparison between alemtuzumab and natalizumab showed similar on-treatment 
annualised relapse rates over four years (mean [95% confidence intervals] 0·20 [0·14-
0·26] vs. 0·19 [0·15-0·23], P=0·78; Figure 4), confirmed by equivalence in the 
cumulative hazard of relapses (P=0·83) and probability of remaining relapse free 
(P=0·65). Cumulative hazard of disability progressionaccumulation events was also 
similar (P=0·60). However, alemtuzumab was associated with lower cumulative 
probability of disability regressionimprovement than natalizumab (hazard ratio 0·35, 
P<0·001). This difference in disability outcomes was also confirmed among patients 
with high pre-baseline relapse activity. 
Sensitivity analyses have confirmed the outcomes of the primary and secondary 
analyses (with the exception of disability outcomes in the comparison of alemtuzumab 
vs. interferon β). The comparisons of the rates of disability progressionaccumulation 
and regressionimprovement events confirmed over 6-months were also largely 
replicated in the sensitivity analysis requiring a 12-month confirmation interval. 
Modifying the matching ratio and caliper, pre-baseline observational period, inclusion 
of secondary progressive MS and minimum on-treatment follow-up did not significantly 
change the overall relapse and disability outcomes (see Table S6). 
Where the primary analysis did not show any significant differences between the 
compared groups, analysis of the minimum detectable effect size was carried out 
(Table S7). The analyses were sufficiently powered to detect minimum differences of 
0·13 relapse per year, 51-53% cumulative hazard of relapses, 35-66% cumulative 
hazard of disability progressionaccumulation and 39-42% cumulative probability of 
disability regressionimprovement. The differences in annualised relapse rates 
observed for alemtuzumab vs. interferon β and fingolimod were resistant to unknown 
confounders with relative magnitudes of >100% and 60% of the reported effect of 
treatment (Hodges-Lehmann Γ), respectively. 
 
 
DISCUSSION 
In this large combined observational propensity score-matched study of patients with 
relapsing-remitting multiple sclerosis, alemtuzumab and natalizumab were equally 
effective in reducing relapse frequency and preventing confirmed disability 
progressionaccumulation over four years. However, natalizumab was more likely to 
lead to disability regressionimprovement, particularly during the first year after 
commencing therapy. Compared to fingolimod, alemtuzumab was superior in reducing 
relapse activity. No differences were found between alemtuzumab and fingolimod  and 
comparable in their ability to modulateing the risk of disability progressionaccumulation 
or regressionimprovement events over three years.  
In order to enable interpretation of these results in the context of the original pivotal 
clinical trials, we have first conducted a comparison of alemtuzumab vs. high-dose 
interferon β-1a. This study has partially replicated the results of these pivotal trials 
comparing the effect of alemtuzumab to high-dose interferon β-1a: alemtuzumab is 
superior to interferon β in suppressing relapse activity and reducing disability accrual 
in patients with previously highly active MS. The observed on-treatment annualised 
relapse rates (0·19 vs. 0·53, alemtuzumab vs. interferon β, respectively) are 
comparable to the relapse rates reported by the CAMMS223 (0·16 vs. 0·54), CARE-
MS1 (0·18 vs. 0·39) and CARE-MS2 (0·26 vs. 0·52) trials. The proportion of patients 
who experienced 6-month confirmed progressionaccumulation of disability at two 
years was similar between the present study (7% vs. 12%, alemtuzumab vs. interferon 
β, respectively) and the CARE-MS1 trial (8% vs. 11%), with neither being significantly 
different. However there was a treatment effect on disability progressionaccumulation 
events in the CAMMS223 (6% vs. 16%) and CARE-MS2 (13% vs. 20%) trials at two 
years. It should be noted that the cohorts are not directly comparable; the 
alemtuzumab trials recruited patients with ≥2 relapses during the preceding two years, 
while inclusion into our primary analysis was based on ≥1 relapse during the preceding 
one year. Our secondary analyses, which only included patients with high pre-baseline 
activity (≥2 relapses during the one year or ≥3 relapses during the two years pre-
baseline) and previous break-through on-treatment relapses showed improved 
disability outcomes in alemtuzumab compared with interferon β (decreased cumulative 
hazard of disability progressionaccumulation and increased probability of disability 
regressionimprovement, respectively). Thus, our results from patients with highly 
active MS are concordant with those produced in the relevant comparative 
alemtuzumab versus interferon β trials. 
The on-treatment annualised relapse rates observed in the natalizumab and fingolimod 
groups (0·19 and 0·34, respectively) are in keeping with the previously reported on-
treatment MS activity form MSBase11,12 and the pivotal trials for natalizumab (0·20-
0·24)22 and are higher than the annualised relapse rates reported in the pivotal trials 
for fingolimod and (0·186-0·420)23,24. In keeping with our previous observation of 
superior control of disease activity after escalating therapy to natalizumab compared 
with fingolimod, alemtuzumab was comparable to natalizumab but superior to 
fingolimod in preventing MS relapses. Both effects were sustained over at least 3-4 
years following the commencement of therapy. While the hazard of disability 
progressionaccumulation was similar for alemtuzumab and both natalizumab and 
fingolimod, treatment with natalizumab increased the probability of confirmed disability 
regressionimprovement more than alemtuzumab. This extends prior observations that 
natalizumab, unlike fingolimod, is likely to increase the probability of partial recovery 
from the previously accumulated neurological disability, in particular during the initial 
years after first MS presentation.12,25 
In the present study, we maximised analytical power by combining several high-quality 
longitudinal observational MS cohorts.5,6 Cumulative follow-up and generalisability 
were maximised by inclusion of a broad spectrum of patients with the minimum follow-
up requirements necessary to evaluate confirmed disability outcomes. Both, treatment-
naïve patients and patients previously exposed to immunotherapies were included.  
Because the assembled study cohort is, by definition, multicentric, we have undertaken 
multiple steps to mitigate the potential biases, including matching, pairwise censoring 
and adjusting the statistical models,10 an approach whose efficacy was demonstrated 
in our previous studies.11,12 The alemtuzumab cohorts were enriched for patients with 
early, highly active disease. Given the large number of patients treated with 
natalizumab, fingolimod or interferon β available from the MSBase cohort, we were 
able to achieve close match on their demographic and clinical characteristics. Because 
the probability of capturing treatment discontinuation was relatively lower in the 
alemtuzumab cohort, we have mitigated the risk of differential follow-up duration by 
pairwise censoring. In addition, we have shown that the results were robust to 
hypothetical unidentified confounders. It is arguable that our approach was 
underpowered to detect some clinically significant treatment effects.  
A The main limitationweakness, in comparison to controlled studies, is the lack of 
systematic and comparable acquisition of safety data and of radiological outcomes. 
Magnetic resonance imaging is an important indicator of subclinical disease activity, 
with potential impact on disease management. If unreported and systematically 
different between the compared cohorts, it could represent an unidentified confounder. 
Another potential confounder is the effect of treating centre. Due to the limited overlap 
between the centres reporting patients treated with alemtuzumab and the three 
comparator therapies, we were not able to match on or adjust for centre, but we have 
mitigated the effect by adjusting the analyses for visit frequency, which served as an 
indicator of follow-up density. In addition, wImportantly, we have shown that theour 
results were robust to hypothetical unidentified confounders of the magnitude >60% of 
the difference in treatment effects. The definition of MS relapses used in our study did 
not require confirmation by change in EDSS, which reflects usual clinical practice; this 
was different from several clinical trials which required EDSS confirmation. This study 
compared treatment outcomes in observational data over 3-5 years. It is worth noting 
that disability accumulation events confirmed over 6-12 months are highly indicative of 
long-term disability outcomes.17 Comparative evaluation of the long-term safety of 
alemtuzumab and natalizumab is therefore warranted, as treatment safety represents 
an important component of disease management strategy. 
In conclusion, we show that - over four three to five years - alemtuzumab is a highly 
effective disease modifying therapy in relapsing-remitting MS, with a treatment effect 
largely comparable to natalizumab, and with greater effect on relapse rate than 
fingolimod or interferon β-1a.  
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RESEARCH IN CONTEXT 
Evidence before this study 
Alemtuzumab, is a highly effective therapy for multiple sclerosis. Similar to 
natalizumab, another highly effective multiple sclerosis therapy, it has shown an 
effective control of multiple sclerosis activity and reduction in disability accrual. In a 
number of scenarios, clinicians and their patients are faced with the decision 
between alemtuzumab or natalizumab (such as early active treatment in aggressive 
multiple sclerosis, escalation of therapy following failure of other therapies or switch 
from natalizumab to alemtuzumab due to a high risk of natalizumab-associated 
serious adverse events). No evidence comparing the efficacy of alemtuzumab and 
natalizumab is available to guide these clinical decisions.  
 
Added value of this study 
This study provides a conclusive evidence comparing effectiveness of alemtuzumab 
vs. natalizumab and fingolimod (another novel immunotherapy) for multiple sclerosis. 
Alemtuzumab and natalizumab show similar effects on relapse activity and disability 
progressionaccumulation but natalizumab is associated with a greater chance of 
early disability reduction. Alemtuzumab is superior to fingolimod in mitigating relapse 
activity. 
 
Implications of all the available evidence 
While alemtuzumab is superior in controlling multiple sclerosis activity relative to 
fingolimod, its efficacy is largely comparable to that of natalizumab. Therefore, 
treatment decisions between alemtuzumab and natalizumab should be primarily 
governed by the therapies’ safety profiles.  
FIGURE LEGENDS 
 
Figure 1 
CONSORT diagram of patient disposition 
 
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis 
 
 
 
Figure 2 
Comparison of the treatment outcomes for alemtuzumab vs. interferon β 
 
 
Figure 3 
Comparison of the treatment outcomes for alemtuzumab vs. fingolimod 
 
 
Figure 4 
Comparison of the treatment outcomes for alemtuzumab vs. natalizumab 
 
Table 1 
Characteristics of the matched patient groups at baseline 
 
 
  
alemtuzumab interferon β d alemtuzumab fingolimod d alemtuzumab natalizumab d 
patients, nr (% female) 124 (73%) 218 (74%) 
 
114 (72%) 195 (73%) 
 
138 (70%) 223 (66%) 
 
age, yr, mean ± SD 33 ± 8 33 ± 9 0·01 33 ± 8 34 ± 10 0·09 33 ± 9 33 ± 10 0·02 
disease duration, yr, 
median (quartiles) 
3·2  
(2-6·2) 
2·6  
(1·2-6·4) 
0·01 3·9  
(2·4-6·6) 
4·2  
(1·6-8·1) 
0·13 3·3  
(2·1-6·3) 
2·7  
(1-7·6) 
0·13 
relapses 12 months pre-
baseline, mean ± SD 
2 ± 1·2 1·9 ± 0·9 0·06 1·8 ± 1·1 1·7 ± 0·8 0·03 2 ± 1·3 2 ± 1 0·03 
disability, EDSS step, 
median (quartiles) 
3  
(2-4) 
3  
(2-4) 
0·12 3  
(1·6-4) 
3  
(1·5-4·5) 
0·00 3  
(2-4·5) 
3  
(2-4·5) 
0·01 
inter-visit interval, months, 
median (quartiles) 
9  
(7-13) 
4  
(2-7) 
0·72 9  
(6-12) 
3  
(2-5) 
1·17 9  
(6-12) 
3  
(1-5) 
1·12 
previous therapies, nr, 
median (quartiles) 
0  
(0-1) 
0  
(0-1) 
0·01 1  
(0-1) 
1  
(0-2) 
0·11 0  
(0-1) 
0  
(0-1) 
0·15 
most active previous therapy, patients 
     Interferon β/Glatiramer 
acetate 
31 (25%) 62 (28%) 
 
46 (40%) 85 (44%) 
 
47 (34%) 97 (43%) 
 
     Teriflunomide 0 0 
 
0 0 
 
0 0 
 
     Dimethyl fumarate 0 0 
 
0 0 
 
0 0 
 
     Fingolimod 0 0 
 
0 0 
 
2 (1%) 4 (2%) 
 
     Natalizumab 3 (2%) 4 (2%) 
 
14 (12%) 22 (11%) 
 
0 0 
 
     Mitoxantrone 3 (2%) 4 (2%) 
 
2 (2%) 5 (3%) 
 
0 0 
 
     other 0 0 
 
0 0 
 
0 0 
 
     none 87 (70%) 148 (68%) 
 
52 (46%) 83 (43%) 
 
89 (64%) 122 (55%) 
 
post-baseline pairwise-
censored follow-up on 
study therapy, yr, median 
(quartiles) 
2·1  
(1·0-3·9) 
2·1  
(1·0-3·9) 
0·00 1·7  
(1·1-2·3) 
1·7  
(1·1-2·3) 
0·00 2·1  
(1·4-3·4) 
2·1  
(1·4-3·4) 
0·00 
 
d, standardised difference (Cohen’s d); SD, standard deviation; EDSS, Expanded Disability Status Scale 
 
